title: Mortality in amnestic mild cognitive impairment: a prospective community study.
abstract: OBJECTIVE
  To assess the hazard of death in persons with and without amnestic mild cognitive impairment (aMCI).
  
  
  METHODS
  From 1987 through 2003, persons with aMCI (n = 243) and an age- and gender-matched reference group of cognitively normal persons in Olmsted County, MN, were recruited through the Mayo Clinic Alzheimer's Disease Patient Registry and followed prospectively through 2004. Survival was estimated using Kaplan-Meier survival curves, and the hazard of death for the aMCI cohort vs the reference cohort was estimated using Cox proportional hazards models.
  
  
  RESULTS
  Over a median follow-up of 5.7 years, persons with aMCI had increased mortality (hazard ratio [HR] = 1.7; 95% CI: 1.3 to 2.3) vs reference subjects. The hazard of death by aMCI subtype was 1.5 in persons with single-domain aMCI (95% CI: 1.1 to 2.1) and 2.9 in persons with multiple-domain aMCI (95% CI: 1.9 to 4.6) vs reference subjects. Analyses restricted to aMCI cases showed an interaction between aMCI subtype and APOE-epsilon4 allele status (p = 0.003). Among aMCI cases with an APOE-epsilon4 allele, there was no difference in mortality between single- and multiple-domain aMCI (HR = 1.2; 95% CI: 0.6 to 2.3). However, among aMCI cases with no APOE-epsilon4 allele, the hazard of death in multiple-domain aMCI was 4.6 (95% CI: 2.3 to 9.1) vs single-domain aMCI.
  
  
  CONCLUSIONS
  Amnestic mild cognitive impairment is associated with increased mortality, which is greater in multiple-domain aMCI than in single-domain aMCI. Mortality in aMCI subtypes may vary by APOE-epsilon4 allele status.
authors.affiliation: Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
authors.forename: A L
authors.initials: AL
authors.lastname: Hunderfund
authors.forename: R O
authors.initials: RO
authors.lastname: Roberts
authors.forename: T C
authors.initials: TC
authors.lastname: Slusser
authors.forename: C L
authors.initials: CL
authors.lastname: Leibson
authors.forename: Y E
authors.initials: YE
authors.lastname: Geda
authors.forename: R J
authors.initials: RJ
authors.lastname: Ivnik
authors.forename: E G
authors.initials: EG
authors.lastname: Tangalos
authors.forename: R C
authors.initials: RC
authors.lastname: Petersen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000647:Amnesia / Q000235:genetics / Q000401:mortality* / Q000523:psychology*; D053327:Apolipoprotein E4 / Q000235:genetics*; D003072:Cognition Disorders / Q000235:genetics / Q000401:mortality* / Q000523:psychology*; D015331:Cohort Studies; D004252:DNA Mutational Analysis; D003704:Dementia / Q000150:complications / Q000401:mortality / Q000523:psychology; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D011446:Prospective Studies; D012985:Software Design; D015996:Survival Rate
chemical_list: D053327:Apolipoprotein E4